Free Flow Medical is developing a next generation medical device technology to treat patients with late stage emphysema, an advanced form of Chronic Obstructive Pulmonary Disease (COPD) that severely limits quality of life, presents the patient with ongoing severe breathlessness and eventual mortality. COPD is the third leading cause of death in the US behind cancer and heart disease. Almost 15.7 million US adults in 2014 have been diagnosed with COPD according Centers for Disease Control and Prevention. Free Flow Medical's founding team is led by inventor/entrepreneur, Mark Mathis. In addition to being involved in a variety of areas within the medical device field since the 1980's with over 100 us patents granted, Mark founded and built PneumRx Inc, where he invented the lung volume reduction coil implant technology that is still the only successful treatment for both heterogenous and homogeneous disease, even in patients who have been tested and found to be CV (collateral ventilation) positive and negative. In early 2015, PneumRx was acquired by BTG (British Technology Group) for $475M. Mark stayed on until late 2016 and then he founded Free Flow Medical in 2017 to develop a next generation coil technology. Free Flow Medical has filed significant patents and developed a next generation device that is designed to provide more consistent and improved patient benefit . The company is partnered with the top clinical experts in the US and Europe who have led and enrolled the majority of patients in all major trials conducted to date in this field. The company was awarded ISO certification and CE Mark approval of the FreeFlow Coil product in late 2020.